Compare e l f Beauty Inc (ELF) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
e l f Beauty Inc vs Zoetis Inc — how do they compare? e l f Beauty Inc trades at $109.45 (market cap $6.25B), while Zoetis Inc trades at $74.49 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 4.8× e l f Beauty Inc's market cap, and Zoetis Inc pays a 2.9% dividend while e l f Beauty Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold e l f Beauty Inc for 25 Days and Zoetis Inc for 70 Days on average.
| ELF | ZTS | |
|---|---|---|
Market Cap | $6.25B | $30.20B |
Volume | 1,099,552 | 6,175,327 |
Sector | Consumer Staples | Health |
52-Week High | $144.97 | $147.53 |
52-Week Low | $49.57 | $69.09 |
Typical Hold Time | 25 Days | 70 Days |
Enterprise Value | $6.84B | $37.76B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ELF Beauty trades at $109.12, up 3.89% today, and is near its R3 resistance level of $109. The stock shows strong technical momentum with bullish moving averages, though RSI levels above 70 indicate potential overbought conditions. Fundamentally, the company reported revenue of $1.31 billion in 2025 with a net income of $112.09 million, and recent earnings beats in Q4 2025, Q1 2026, and Q2 2026 highlight operational strength. Expansion into Europe via Sephora for the rhode brand and marketing initiatives like the 'Mirror Mix' album signal aggressive growth strategies.
The outlook for ELF is positive given earnings momentum and international expansion, but the high P/E ratio of 108.12 poses valuation risks. Analyst consensus is a 'Buy' with a price target of $95.91, below the current price, suggesting limited near-term upside. Key risks include competitive pressures in the beauty sector and sensitivity to consumer spending trends. Institutional buying activity, such as State Street Corp's increased stake, supports confidence in long-term growth.
Zoetis (ZTS) trades at $74.38, up 3.96% in the last session, with a bullish technical signal and strong profitability metrics including a 71.67% gross margin and 27.69% net income margin. Recent earnings show mixed results, with a beat in Q2 2026 but a miss in Q1 2026, while Q3 2026 results are pending. The company maintains robust cash flow from operations of $2.90B in 2025 and a solid balance sheet with $1.99B in cash. Analyst consensus is a Buy with a $87.33 price target, though sentiment is tempered by near-term competitive pressures.
The outlook for ZTS is cautiously optimistic, supported by industry-leading margins and a diversified product portfolio, but faces headwinds from U.S. companion animal market weakness and increased competition. Investment opportunity lies in its undervalued P/E of 11.92 relative to growth potential, while risks include pricing erosion and volume declines. The stock's current level near resistance at $74 suggests potential for consolidation before further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About e l f Beauty Inc
e.l.f. Beauty is a leading cosmetics company offering high-quality, 100% vegan, and cruelty-free products. It is known for its affordable and prestige-quality makeup and skincare items for a diverse global audience.
Read more on ELF →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
